Hims & Hers shares soared as Novo Nordisk dropped its GLP-1 lawsuit. But there’s reason to still sell HIMS stock today. Find out more!
NEW YORK , March 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised...
NEW YORK , Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised...
Novo Nordisk stock tanks as CagriSema appears inferior to Eli Lilly’s competing weight-loss drug in a late-stage trial. But NVO shares are still worth buying at current levels.
The DJS Law Group announces that it is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSE: NVO ) for violations of the...
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or “the Company”)...
HIMS is down 48% in the past month following a Novo Nordisk lawsuit. But, analysts expect record revenue when the company reports earnings this month.
Hims & Hers shares crater as Novo Nordisk files a lawsuit against the telehealth firm. BofA analysts see significant further downside in HIMS stock.
Investors had little time to celebrate Eli Lilly's huge post-earnings gain. While Hims & Hers Health knocked shares down, LLY remains a healthcare stalwart.
Volatility returned to markets yesterday, triggering a tech rout. Among the unusually active options on Thursday were 278 calls and puts with Vol/OI ratios of 15 or higher. Among them, these 3 stocks offer...